| Literature DB >> 36128524 |
Ravindra Kumar Upadhyay1, Keshav Kumar Saini1, Nidhi Deswal1, Tejveer Singh2, Kailash Pati Tripathi3, Parshant Kaushik3, Najam Akhtar Shakil3, Alok Chandra Bharti4, Rakesh Kumar1.
Abstract
In order to explore new antifungal agrochemicals, we reported the synthesis of two series 5a-f, 6 and 7a-f, 8 of benzothiazole-appended bis-triazole derivative-based structural isomers using a molecular hybridization approach. The synthesized compounds were tested for fungal growth inhibition against the plant pathogen Rhizoctonia solani. All the synthesized compounds showed excellent antifungal activity in their minimum concentrations (10-0.62 μM). Among all the synthetics, compounds 5b (ED50: 2.33 μM), 5f (ED50: 0.96 μM), and 7f (ED50: 1.48 μM) exerted a superior inhibitory effect in comparison to the commercially available fungicide, hexaconazole (ED50: 2.44 μM). The binding interactions of the active compounds 5f, 7f, 6, and 8 within the active site of the sterol 14α-demethylase enzyme were studied with the help of molecular docking studies. The studies revealed that these hybrid pharmacophores could be used as an important intermediate to demonstrate new structural isomer-based fungicides. This journal is © The Royal Society of Chemistry.Entities:
Year: 2022 PMID: 36128524 PMCID: PMC9425831 DOI: 10.1039/d2ra04465j
Source DB: PubMed Journal: RSC Adv ISSN: 2046-2069 Impact factor: 4.036
Fig. 1Structures of some antifungal drugs (I–VII).
Fig. 2Design protocol of the target compounds.
Scheme 1Synthesis of bis-propargylated 2-aminobenzothiazoles.
Optimization of the reaction conditions of Scheme 1 for the synthesis of compounds 1 and 2
| Entry | Solvent | Base | Temp (°C) | Yield (%) |
|---|---|---|---|---|
| i | THF | K2CO3 | 70 | No reaction |
|
|
|
|
|
|
| iii | DMF | K2CO3 | 70 | 95 : 5 |
| iv | DMF | NaH | 70 | 90 : 10 |
| v | Ethanol : water | K2CO3 | 70 | No reaction |
| vi | Dioxane | K2CO3 | 70 | No reaction |
Scheme 2A possible mechanism for the synthesis of compounds 1 and 2.
Scheme 3Synthesis of benzothiazole-appended bis-triazole derivatives 5a–e and 6.
Scheme 4Synthesis of benzothiazole-appended bis-triazole derivatives 7a–e and 8.
Scheme 5Synthesis of benzothiazole-appended bis-triazole derivatives containing 3-pyrrolylisatin 5f and 7f from 5e and 7e, respectively.
Structures of the synthesized benzothiazole-appended bis-triazole derivatives 5a–f, and 6
| S. N. | Structure of compounds | Yields (%) | Melting point (°C) |
|---|---|---|---|
| 1 |
| 78 | 154–156 |
| 2 |
| 80 | 156–158 |
| 3 |
| 90 | 161–164 |
| 4 |
| 89 | 185–187 |
| 5 |
| 90 | 171–172 |
| 6 |
| 70 | 171–172 |
| 7 |
| 85 | 193–197 |
Structures of the synthesized b-enzothiazole-appended bis-triazole derivatives 7a–f, and 8
| S. N. | Structure of compounds | Yields (%) | Melting point (°C) |
|---|---|---|---|
| 1 |
| 70 | 165–168 |
| 2 |
| 75 | 175–177 |
| 3 |
| 80 | 168–171 |
| 4 |
| 75 | 167–169 |
| 5 |
| 76 | 175–177 |
| 6 |
| 75 | 174–175 |
| 7 |
| 80 | 197–199 |
Fig. 3In vitro studies of the synthesized compounds at various concentrations using PDA culture media.
Fig. 4Antifungal evaluation against plant pathogen Rhizoctonia solani using 5a–f, 6 and 7a–f, 8 from 10 μM to 0.62 μM.
Percent inhibition of all the treated compounds at different concentrations
| Compounds | 10 μM | 5 μM | 2.5 μM | 1.25 μM | 0.62 μM |
|---|---|---|---|---|---|
| 5a | 70.00 ± 6.7 | 61.94 ± 3.6 | 49.16 ± 1.1 | 40.55 ± 2.3 | 29.16 ± 1.1 |
| 5b |
|
|
|
|
|
| 5c | 73.33 ± 0.9 | 58.88 ± 2.4 | 48.88 ± 2.0 | 34.44 ± 0.9 | 22.50 ± 1.1 |
| 5d | 72.22 ± 0.9 | 69.16 ± 1.4 | 51.38 ± 2.3 | 34.72 ± 1.4 | 22.50 ± 3.6 |
| 5e | 74.16 ± 2.5 | 54.44 ± 1.6 | 42.77 ± 1.4 | 30.00 ± 1.6 | 21.11 ± 1.6 |
| 5f |
|
|
|
|
|
| 6 | 78.88 ± 0.9 | 60.27 ± 1.7 | 49.72 ± 1.1 | 35.00 ± 1.4 | 27.77 ± 1.1 |
| 7a | 69.16 ± 8.2 | 61.38 ± 2.9 | 48.61 ± 0.6 | 40.27 ± 0.6 | 28.61 ± 1.1 |
| 7b | 65.27 ± 7.6 | 60.27 ± 1.4 | 47.77 ± 3.3 | 41.66 ± 6.9 | 28.88 ± 4.3 |
| 7c | 68.61 ± 9.3 | 61.11 ± 3.0 | 48.05 ± 1.7 | 39.72 ± 1.4 | 28.05 ± 1.9 |
| 7d | 65.83 ± 9.8 | 63.05 ± 3.0 | 47.77 ± 0.6 | 42.77 ± 8.2 | 29.44 ± 1.9 |
| 7e | 77.22 ± 2.1 | 57.5 ± 1.1 | 48.33 ± 1.4 | 33.61 ± 1.1 | 23.61 ± 1.1 |
| 7f |
|
|
|
|
|
| 8 | 67.77 ± 9.2 | 61.11 ± 4.3 | 48.33 ± 3.6 | 42.50 ± 7.6 | 29.72 ± 6.2 |
|
|
|
|
|
|
|
ED50 values for all the treated compounds for the plant pathogen Rhizoctonia solani
| Compounds | ED50 | Lower fiducial limit | Upper fiducial limit |
| Regression equation |
|---|---|---|---|---|---|
| 5a | 2.47 | 1.82 | 3.349 | 0.165 | 0.96 |
| 5b |
|
|
|
|
|
| 5c | 2.87 | 2.259 | 3.689 | 0.247 | 1.28 |
| 5d |
|
|
|
|
|
| 5e | 3.38 | 2.695 | 4.372 | 1.247 | 1.6 |
| 5f |
|
|
|
|
|
| 6 | 2.50 | 1.992 | 3.147 | 2.299 | 1.12 |
| 7a | 2.56 | 1.89 | 3.502 | 0.212 | 0.96 |
| 7b | 2.75 | 1.955 | 3.951 | 0.718 | 0.8 |
| 7c | 2.65 | 1.964 | 3.636 | 0.251 | 0.96 |
| 7d | 2.51 | 1.801 | 3.528 | 0.341 | 0.96 |
| 7e | 2.77 | 2.208 | 3.528 | 1.35 | 1.6 |
| 7f |
|
|
|
|
|
| 8 | 2.54 | 1.807 | 3.59 | 1.431 | 0.96 |
|
|
| 1.813 | 3.318 | 0.164 | 0.96 |
ED50 is the effective dose that causes 50% of the maximal cause.
The interaction analysis of the molecular docking study on 14α-demethylase CYP51 with the benzothiazole-appended bis-triazole derivative-based structural isomers
| S. N. | Drug name (ligand) | Binding energy (kcal mol−1) | Interaction with amino acids |
|---|---|---|---|
| 1 | 6 | −8.5 | PRO A: 83, HIDA: 84, GLU A: 85, HID A: 86, SER A: 87, ARG A: 88, LEU A: 91, GLU A: 409, GLY A: 410, ALA A: 417 |
| ARG B: 347, ARG B: 344, GLU B: 343, PRO B: 340, PHE B: 412, ARG B: 405, ASP B: 405, GLU B: 406, LYS B: 426, GLN B: 425 | |||
| 2 | 8 | −7.1 | ASN: 141, HID: 148, ASN: 152, ASN: 177, GLN: 181, CYS: 182, LEU: 183, PHE: 184, GLY: 185, GLU: 186, ARG: 189, LYS: 190, ASP: 193, ALA: 194, ARG: 195, SER: 257, THR: 258, SER: 259, ASP: 260 |
| 3 | 5f |
| HID A: 86, SER A: 87, PHE A: 90, LEU A: 91, PRO A: 92, ARG A: 93, VAL A: 96, ASP B: 337, PRO B: 340, GLU B: 343, ARG B: 344, ARG B: 347, GLU B: 348, ARG B: 351, ASP A: 366, VAL A: 367, LYS A: 368, ASP B: 405, GLU A: 409, GLY A: 410, ALA A: 417 |
| 4 | 7f | −8.4 | ALA A: 318, LYS A: 321, GLU A: 322, PHE A: 326, ASP A: 337, GLU A: 338, PRO A: 340, PHE A: 341, GLU A: 343, ARG A: 344 GLN B: 329, ASN B: 331 |
| 5 |
|
| LYS: 138, GLN: 140, ASN: 141, PHE: 142, GLN: 181, CYS: 182, LEU: 183, SER: 259, ASP: 260, LEU: 261, GLU: 133 |
Fig. 62D and 3D images of compound 5f with target protein CYP51.